Preventing a protein called AGTR2 from going about its work — either by removing it through genetic engineering or by using…
Articles by José Lopes, PhD
The adaptation of bacteria Pseudomonas aeruginosa to the lungs of cystic fibrosis (CF) patients may make them more susceptible…
A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in…
Vertex Pharmaceuticals’ treatments for cystic fibrosis (CF) all provide considerable benefits, but their pricing is not transparent and does…
New research provides insights into how bacteria “talk” to each other in lung infections, which could provide strategies to block…
Clinical centers around the world differ in the standards they use when considering cystic fibrosis (CF) patients with…
An antibacterial compound found in toothpaste, called triclosan, may be part of a future cystic fibrosis (CF) treatment, a…
Tobramycin, an antibiotic often used to treat acute lung infections in cystic fibrosis patients, is safe for once-a-day use in children…
Abnormalities in continuous glucose monitoring (CGM) measures correlate with a decline in lung function in children and adolescents with…
AB569, Arch Biopartners’ treatment candidate for bacterial infections in patients with cystic fibrosis, chronic obstructive pulmonary disease…